Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards by Lucatelli, Pierleone et al.
CLINICAL STUDYFrom the Vascular and
G.D.R., B.R., M.B., C.C
Division (S.G.C.), Depa
Surgery and Organ Tr
Medicine (F.F, A.C.), S
ment of Medical Imagin
Polo di Monserrato, C
received October 21,
spondence to P.L., Vas
Diagnostic Service, Sa
Rome 00161, Italy; E-mPolyethylene Glycol Epirubicin-Loaded
Transcatheter Arterial Chemoembolization
Procedures Utilizing a Combined Approach with
100 and 200 μm Microspheres: A Promising
Alternative to Current Standards
Pierleone Lucatelli, MD, PhD, EBIR, Renato Argiro, MD,
Gianluca De Rubeis, MD, Bianca Rocco, MD,
Stefano Ginanni Corradini, MD, PhD, Mario Corona, MD,
Pier Giorgio Nardis, MD, Luca Saba, MD, Gianluca Mennini, MD,
Francesco Fiorentino, MD, Alessandro Corsi, MD, Carlo Catalano, MD, and
Mario Bezzi, MD, EBIRABSTRACT
Purpose: To report clinical effectiveness, toxicity profile, and prognostic factors of combined 100 μm ± 25 and 200 μm ± 50
epirubicin-loaded polyethylene glycol (PEG) microsphere drug-eluting embolic transcatheter arterial chemoembolization protocol in
patients with hepatocellular carcinoma.
Materials and Methods: In this prospective, single-center, single-arm study with 18 months of follow-up, 36 consecutive patients
(mean age 69.9 y ± 10.8; 26 men, 10 women; 54 naïve lesions) were treated. Embolization was initiated with 100 μm ± 25 micro-
spheres, and if stasis (10 heart beats) was not achieved, 200 μm ± 50 microspheres were administered. Each syringe (2 mL) of PEG
microsphere was loaded with 50 mg of epirubicin. Results were evaluated using Modified Response Evaluation Criteria In Solid Tumors
with multidetector computed tomography/magnetic resonance imaging at 1, 3–6, 9–12, and 15–18 months. Toxicity profile was assessed
by laboratory testing before and after the procedure. Complications were recorded. Postembolization syndrome (PES) was defined as
onset of fever/nausea/pain after the procedure. Patient/lesion characteristics and treatment results were correlated with predicted outcome
using regression analysis. Child-Pugh score was A in 86.1% of patients (31/36) and B in 13.9% (5/36).
Results: In 10 of 21 lesions, < 2 cm in diameter (47.5%) stasis was achieved with 100 μm ± 25 microspheres only, whereas all other
lesions required adjunctive treatment with 200 μm ± 50 microspheres. Reported adverse events were grade 1 acute liver bile duct injury
(3/39 cases, 7.7%) and PES (grade 2; 3/39 cases, 7.7%). Complete response (CR) at 1, 3–6, 9–12, and 15–18 months was 61.1%, 65.5%,
63.63%, and 62.5%. Objective response (CR þ partial response) at 1, 3–6, 9–12, and 15–18 months was 83.3%, 65.85%, 63.63%, and
62.5%. No single factor (laboratory testing, etiology, patient status, hepatic status, tumor characteristics, administration protocol) pre-
dicted outcomes except for albumin level at baseline for CR (P < .05, odds ratio ¼ 1.09).
Conclusions: The combined microsphere sizing strategy was technically feasible and yielded promising results in terms of effec-
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AE ¼ adverse event, AUC ¼ area under the curve, CR ¼ complete response, DC ¼ disease control, DEE ¼ drug-eluting embolic,
HCC ¼ hepatocellular carcinoma, mRECIST ¼ Modified Response Evaluation Criteria In Solid Tumors, PD ¼ progressive disease,
PEG ¼ polyethylene glycol, PES ¼ postembolization syndrome, PR ¼ partial response, RS ¼ radiation segmentectomy, SD ¼ stable
diseaseDrug-eluting embolic (DEE) transcatheter arterial chemo-
embolization is a variant of conventional chemoembolization
with ethiodized oil (Lipiodol; Guerbet, Villepinte, France).
Use of microspheres in DEE transcatheter arterial chemo-
embolization should in theory allow for better procedure
standardization, resulting in longer time to ischemia and
improved drug release (1,2). Most trials and meta-analyses
aiming to demonstrate the superiority of DEE transcatheter
arterial chemoembolization over conventional chemo-
embolization reached statistically significant results in terms
of tumor control, tolerability, toxicity, and pain onset (3–5).
Despite the clearly defined technical specifications for
DEE transcatheter arterial chemoembolization (6), no stan-
dard administration protocol was designated among different
sites regarding diameter of the used particles. At the present
time, there is no clinical or outcome evidence in favor of 1
published protocol above all others regarding the achieved
clinical outcome. More recently, the focus of DEE trans-
catheter arterial chemoembolization research has shifted to-
ward the use of smaller caliber particles. Padia et al (7)
demonstrated that patients treated with particles < 150 μm
had better outcomes than patients treated with particles> 300
μm. However, evidence from studies about the effectiveness
of particles < 150 μm showed different complete response
(CR) rates at 3 months, ranging from 17.8% to 48% (8–10).
Particles < 100 μm act as devascularization agents,
whereas particles > 150 μm exert hypoxia/anoxia effects
(11). The hypothesis was that the combination of particles of
2 different calibers (100 μm ± 25 and 200 μm ± 50) could
lead to profound blood stasis at the tumor level, while
concomitantly allowing for a more proximal embolization.
The theoretical assumption is that achieving better tumor
blood deprivation can further enhance the overall response
rates. The aim of this prospective, single-center, single-arm
study was to determine the clinical outcome of an epirubicin
combined embolization protocol comprising 100 μm ± 25/
200 μm ± 50 polyethylene glycol (PEG) microspheres
(LifePearl; Terumo, Tokyo, Japan) using Modified Response
Evaluation Criteria In Solid Tumors (mRECIST).MATERIALS AND METHODS
This study was approved by the local ethical committee.
Between May 2015 and February 2017, 36 consecutive
patients (mean age 69.9 y ± 10.7; range, 48–89 y; 26 men)
with 54 hepatocellular carcinoma (HCC) tumors diagnosed
by accepted radiological features and evidence of liver
cirrhosis were enrolled and treated (12,13). Clinical and
demographic characteristics are summarized in Table 1.Inclusion and Exclusion Criteria
Inclusion criteria, established by consensus within a multi-
disciplinary board (including a transplant surgeon, an inter-
ventional radiologist, a body radiologist, and a hepatologist),
included all nonpreviously treated lesions, Child-Pugh score
up to B8, and Barcelona Clinic Liver Cancer stage up to B.
All enrolled patients had a previous diagnosis of typical
hypervascular HCC and were considered ineligible for
curative treatments (surgical resection or percutaneous
ablative treatments) because of anatomic or disease-related
(total HCC burden) factors. Diagnosis was determined
according to the American Association for the Study of Liver
Disease guidelines (13), with agreement among multi-
detector computed tomography (CT) and magnetic reso-
nance (MR) imaging in all patients. Exclusion criteria were
Child-Pugh score C, Barcelona Clinic Liver Cancer stage
C, portal vein thrombosis, previous systemic treatment,
platelet count< 50,000/mm3, and bilirubin level> 3 mg/dL.DEE Transcatheter Arterial
Chemoembolization Technique
The DEE transcatheter arterial chemoembolization protocol
was standardized before patient enrollment to reduce
potential bias. All procedures were performed by 2 inter-
ventional radiologists (P.L. and R.A., 10 y and 8 y of
experience, respectively).
Procedures were performed by femoral access in all cases.
Detailed mapping of liver tumor feeders was performed with
digital subtraction angiography (posteroanterior and right
anterior oblique 25) and dual-phase cone-beam CT after
positioning a 4-F catheterwithin the commonor proper hepatic
artery to exclude the presence of parasitic extrahepatic feeders.
After identifying the tumors’ feeders, catheterizations were
performed with the coaxial technique with a 2.7-F micro-
catheter (Progreat; Terumo Europe NV, Leuven, Belgium), as
selectively as possible (meaning as close to the tumor as
technically feasible). PEG microspheres were loaded with
50 mg epirubicin per syringe consisting of 2 mL of embolic
material (2,450,000microspheres in 100 μm± 25 and 310,000
microspheres in 200 μm ± 50) diluted with contrast materials
(350 mmol/mL) to reach 20 mL. The embolization protocol
was sequential, starting with 100 μm ± 25 PEG microspheres,
immediately followed by a second embolization with PEG
microspheres with a diameter of 200 μm ± 50. The emboli-
zation technical endpoint was 10 heart beats stasis. If the stasis
was achieved with the 100 μm ± 25 particles, the adjunctive
200 μm ± 50 microspheres were not administered. The total
dose of microspheres in milliliters and chemotherapeutic drug








< 2 cm 21
2–3 cm 16









mean ± SD (range)
16.81 ± 31.63 (0.69–189.05)
Age, y, mean ± SD (range) 69.89 ± 10.77 (48–89)
Sex, male/female 26/10







Alcohol-related cirrhosis 4 (11.11%)
Cryptogenetic cirrhosis 4 (11.11%)
Mixed 7 (19.44%)
Autoimmune cirrhosis 1 (2.77%)
HCC in healthy liver 1 (2.77%)
MELD
< 15 33 (92.10%)
 15 3 (7.89%)
MELDNa
< 15 32 (84.21%)








< 7 μg/L 11 (28.94%)
7–200 μg/L 13 (34.21%)
 200 μg/L 14 (36.84%)
AFP ¼ a-fetoprotein; HBV ¼ hepatitis B virus; HCC ¼ hepato-
cellular carcinoma; HCV ¼ hepatitis C virus; MELD ¼Model for
End-Stage Liver Disease; MELDNa ¼ Model for End-Stage
Liver Disease Sodium.
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2019 3in milligrams was recorded. Repeated embolization sessions
were performed during follow-up “on-demand” (1). Retreat-
ments were performed only in partial response (PR) cases, if
deemed more useful than other procedures (ie, percutaneous
ablation of residual viable tissue).
Follow-up imaging timelines included multidetector CT
and MR imaging within 1 month before planned treatmentand multidetector CT and MR imaging follow-up at 1, 3–6,
9–12, and 15–18 months after the initial chemoembolization
procedure. Embolization results were evaluated according to
mRECIST (14). Patients were considered dropouts from the
study in cases of retreatment performed with another modality
(eg, radiofrequency ablation, degradable starch microsphere
transcatheter arterial chemoembolization, radioembolization,
systemic antineoangiogenic treatment), liver transplantation,
or worsening of clinical condition owing to HCC.DEE Transcatheter Arterial
Chemoembolization Scoring
To compare the different transcatheter arterial chemo-
embolization procedures, based on the level of the micro-
catheter position at the time of embolization, the procedures
were categorized as 0, superselective; 1, subsegmental; 2,
segmental; 3, multisegmental; and 4, lobar.Study Endpoints
The primary endpoints of the study were (i) tumor response
at 1 month, 3–6 months, 9–12 months, and 15–18 months;
(ii) correlation between tumor dimension and total admin-
istered dose (100 μm and 200 μm microspheres) with the
corresponding mRECIST response; and (iii) toxicity during
the entire follow-up period. mRECIST categorization by
Lencioni et al (14) defines CR as disappearance of any
intratumoral arterial enhancement in all target lesions, PR as
decrease > 30% in the sum of diameters of viable target
lesions (taking as reference the baseline sum of the
diameters of target lesions), stable disease (SD) as any cases
that do not qualify for either PR or progressive disease (PD),
and PD as an increase of at least 20% in the sum of the
diameters of viable target lesions (taking as reference the
smallest sum of the diameters of viable target lesions
recorded since treatment started). Objective response is
defined as CR þ PR rate; disease control (DC) is defined as
CR þ PR þ SD rate. As a secondary endpoint, analysis of
the correlation between mRECIST classification after the
procedure and histologic analysis was performed on an
explanted liver, assessing microsphere deposition within the
tumor and the surrounding vasculature.
To assess the safety profile of the sequential DEE trans-
catheter arterial chemoembolization protocol, monitoring of
liver enzymes was performed immediately before the pro-
cedure, 36–48 hours after the procedure, and during the
scheduled imaging follow-up visits. Liver function tests
included serum total and conjugated bilirubin, aspartate
aminotransferase, alanine aminotransferase, alkaline phos-
phatase, g-glutamyltransferase, and albumin measurements.
Prothrombin time (international normalized ratio) and blood
cell counts were also evaluated.
All adverse events (AEs) were recorded and graded
according to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events, Version 4.03 (15).
Postembolization syndrome (PES) was defined as the onset
of fever and/or nausea and/or pain after the procedure and a
Figure 1. Study flowchart. FU ¼ follow-up; OLT ¼ orthotopic
liver transplantation. *All chemoembolizations counted were on
catheter-naïve lesions.
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Asymptomatic liver bile duct injuries were defined as
segmental duct dilatation, biloma formation, onset after
treatment not associated with increase of bilirubin level, and
neither fever nor cholangitis (16).
To identify prognostic factors associated with tumor
response, variables were evaluated in 6 data sets, including
laboratory analysis (aspartate aminotransferase, alanine
aminotransferase, a-fetoprotein, g-glutamyltransferase, total
bilirubin, direct bilirubin, albumin, number of platelets,
white blood cells, number of neutrophils, percentage of
neutrophils, international normalized ratio, creatinine, and
sodium), etiology (hepatitis C virus, alcohol-related, auto-
immunity, cryptogenic, mixed, and normal liver), previous
status (portal thrombosis, biliary duct dilatation, chemo-
therapy, previous treatment, and transjugular intrahepatic
portosystemic shunt), hepatic status (Child-Pugh, Model for
End-Stage Liver Disease, Model for End-Stage Liver Dis-
ease Sodium, and a-fetoprotein), tumor characteristics
(monofocal, monolobar, lesion number, diameter, volume,
hypervascular, fat degeneration, capsule, infiltration,
shadow margin, and partial necrosis), and epirubicin
administration protocol (epirubicin dose, percentage of
administered 100 μm and 200 μm microspheres). The var-
iables were grouped into 6 data sets to simplify statistical
analysis and avoid potentially linear regression overfitting.
The division was performed according to a careful clinical
and statistical evaluation by a priori matching of the vari-
ables based on different pathophysiologic fields.Statistical Analysis
Continuous variables were expressed as mean ± SD.
Kolmogorov-Smirnov z test was performed to assess
normality distribution of laboratory analysis before and after
the procedure. The Student t test for paired samples was used
for variables with normality distribution, and the Wilcoxon
rank sum test was used for variables with nonnormal dis-
tribution. A logistic regression using the “enter” selection
model and the Cox and Snell and the Nagerlkerke models
was performed to test the predictive power of each data set
(laboratory analysis, etiology, previous status, hepatic status,
tumor characteristics, epirubicin administration protocol) to
predict CR and DC at baseline and follow-up at 3–6 months,
9–12 months, and 15–18 months. Statistical analysis was
performed using MedCalc 8.0 software (MedCalc Software
bvba, Ostend, Belgium). P values < .05 were considered
statistically significant, and all P values were calculated us-
ing a 2-tailed significance level. Receiver operating charac-
teristic curve analysis was performed, and the model was
characterized by the area under the curve (AUC).RESULTS
To prospectively treat the 36 enrolled patients (54 tumors),
39 transcatheter arterial chemoembolization sessions were
performed. During follow-up, 3 patients with 3 tumors(3/54, 5.55%; 1 tumor < 2 cm, 1 tumor 2–3 cm, 1 tumor
> 3 cm) needed a second transcatheter arterial chemo-
embolization treatment.Clinical Response
The number of patients/tumors during the follow-up period
was 36/54 at 1 month, 28/41 at 3–6 months, 20/33 at 9–12
months, and 11/16 at 15–18 months. Figure 1 shows the
detailed flowchart. CR at 1 month, 3–6 months, 9–12
months, and 15–18 months was 61.1% (33/54), 65.9%
(27/41), 63.6% (21/33), and 62.5% (10/16). Objective
response at 1 month, 3–6 months, 9–12 months, and 15–
18 months was 83.3% (45/54), 65.9% (27/41), 63.6%
(21/33), and 62.5% (10/16) (Fig 2a–d). Table 2 shows the
CR analysis. The progression-free survival is shown in
Figure 3. Table 3 summarizes the tumor response of the
entire cohort at different time points and according to
different tumor sizes (< 2 cm vs 2–3 cm vs > 3 cm); in
particular, 10 of 21 (47.6%) tumors < 2 cm needed only
100 μm ± 25 microspheres (10/54 [18.5%] among all
tumors).
By evaluating the selectivity of the DEE transcatheter
arterial chemoembolization procedure, a superselective
embolization (score 0) was obtained for 25 tumors (46.29%;
6 tumors  2 cm, 9 tumors 2–3 cm, and 10 tumors  3 cm).
A subsegmental embolization (score 1) was obtained for 29
tumors (53.7%; 15 tumors  2 cm, 7 tumors 2–3 cm, and 7
tumors  3 cm) (Figs 2a–d, 4a, b).Safety Evaluation
The comparison of laboratory tests before and 36–48
hours after the procedure demonstrated a statistically
Figure 2. A 58-year-old man with hepatitis C virus–related cirrhosis (Barcelona Clinic Liver Cancer stage A, Child-Pugh score A5) with a
35  34 mm stage 5 HCC adjacent to the duodenum. (a, b)Multiphasic CT demonstrates typical wash-in (arrow) in the arterial phase (a)
and late wash-out at the delayed phase (b). (c) Superselective catheterization (score 0) was achieved, and 100% of 100-μm microsphere
and 47.5% of 200-μmmicrosphere were administered. (d) Follow-up CT at 12 months after the procedure demonstrates no residual vital
tissue (arrow), categorizing the patient as having CR.
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2019 5significant variation in neutrophil percentage (55.8% vs
72.3%, P < .01). Among clinical AEs, mild (grade 2)
PES occurred in 3 of 39 treatments (7.69%), characterized
by fever in 2 patients and associated with nausea and pain
in 1 patient within 24 hours. The median visual analog
scale score was 3. All AEs were resolved with medical
therapy alone within the first 24 hours after treatment and
did not require prolonged hospitalization in any case.
Asymptomatic (grade 1) liver bile duct injuries occurred
after 3 transcatheter arterial chemoembolizations (7.69%),
and they were diagnosed on follow-up images in all
cases.Pathologic Evaluation
Five patients with 10 treated tumors underwent orthotopic
liver transplantation. Histologic analysis of the explanted
liver was concordant with radiologic response before
transplantation; in particular, 4 tumors classified as CR
demonstrated histologic necrosis > 90% (Fig 5a–c), and the
remaining 6 tumors (1 PR, 4 SD, 1 PD) demonstrated a
residual tumor > 50%. Assessment of microsphere
deposition on 1 explanted liver confirmed a statistically
significant difference (P < .01) in terms of microsphere
localization between the intranodular location and aperinodular arterial vessel. In particular, 100 μm ± 25
microspheres were mainly located in the intranodular
location, whereas 200 μm ± 50 microspheres were located
in both the intranodular and the perinodular arterial vessel
locations (Fig 5a–c).Predictive Model Logistic Regression
Analysis
The only independent factor for predicting outcome was
albumin for predicting CR at 1 month (odds ratio ¼ 1.09;
95% confidence interval, 1.0134–1.1701; P < .05) but with
a poorly fit model (Hosmer and Lemeshow c2 test ¼
13.4702, P ¼ .142). No other single variable tested inside
the respective set showed a significant propensity to pre-
dict outcome (CR, SD, PR, PD, and DC at 1 month, 3–6
months, 9–12 months, and 15–18 months). In addition,
some data sets had significant statistical power to prog-
nosticate the related outcome, in particular, laboratory
analysis for CR at 3–6 months (AUC ¼ 0.95) and for DC
at 9–12 months (AUC ¼ 0.98), hepatic status for DC at 3–
6 months (AUC ¼ 0.99), and tumor characteristics for CR
at baseline (AUC ¼ 0.86) and at 3–6 months (AUC ¼
0.91) (more detailed parameters are shown in Table 4 and
Fig 6a–d).
Table 2. Per-Tumor Summary Results
Tumor Response 1 Month 3–6 Months 9–12 Months 15–18 Months
CR 33/54 (61.1) 27/41 (65.9) 21/33 (63.6) 10/16 (62.5)
PR 12/54 (22.2) 0/41 (0) 0/33 (0) 0/16 (0)
OR (CR þ PR) 45/54 (83.3) 27/41 (65.9) 21/33 (63.6) 10/16 (62.5)
SD 9/54 (16.7) 11/41 (26.82) 9/33 (27.3) 5/16 (31.3)
DC (OR þ SD) 54/54 (100) 38/41 (92.7) 30/33 (90.9) 15/16 (93.7)
PD 0/0 (0) 3/41 (7.31) 3/33 (9.1) 1/16 (6.35)
Note–Values presented as number of tumors (%).
CR ¼ complete response; DC ¼ disease control; OR ¼ objective response; PD ¼ progressive disease; PR ¼ partial response; SD ¼
stable disease.
Figure 3. Progression-free survival Kaplan-Meier curve.
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The present study reports oncologic outcomes of a com-
bined embolization protocol consisting of epirubicin-
loaded PEG microspheres 100 μm ± 25 followed by
200 μm ± 50 within a single procedure. In particular, a
CR rate of 62.5% (10 of 16) and a DC rate of 93.7% (15
of 16) at 15–18 months’ follow-up was observed. The 200
μm ± 50 microspheres were required to achieve stasis for
nearly half of the tumors < 2 cm (10 of 21 [47.6%]) and
always for tumors > 2 cm (33 of 33 [100%]). The liter-
ature regarding DEE transcatheter arterial chemo-
embolization performed with particles < 100 μm as a
unique embolic agent reports 3-month CR rates of 17.8%–
48% alongside high reintervention rates (8–10,17). In a
randomized controlled trial comparing DEE transcatheter
arterial chemoembolization versus conventional trans-
catheter arterial chemoembolization, Golfieri et al (4)
reached a CR of 51.7%, 58.2%, 68.7%, 56.6%, and
48.9% for DEE transcatheter arterial chemoembolization
and 63.2%, 58.0%, 63.5%, 55.4% and 44.8% for con-
ventional chemoembolization at 1 month, 3 months, 6
months, 9 months, and 12 months. There is limited evi-
dence for PEG microsphere usage in the DEE transcatheter
arterial chemoembolization technique for HCC treatment.
Aliberti et al (10) obtained promising results using 100 μm± 25 doxorubicin-loaded PEG microspheres, reporting CR
rates of 50%, 48%, and 43% at 1 month, 3 months, and
6 months.
The rates of response observed in this study could be
attributed to the combination of several factors. First, PEG
microspheres demonstrated high drug elution for epirubicin
in vitro (35% at 5 h), with a postloading size shrinkage of
24% and a long time in suspension (357 s ± 7) (18).
Second, as suggested by the microscopic anatomopatho-
logic analysis of spatial disposition of PEG microspheres
in liver specimens, the combination of 2 different micro-
sphere diameters can further enhance the tumor emboli-
zation. The 100 μm ± 25 microspheres, deposited mainly
intratumorally, could increase the dose of delivered drug to
the target, whereas the 200 μm ± 50 microspheres, by
depositing not only inside the tumor but also within the
peritumoral arterioles, could enhance ischemia. This
concept is supported by the fact that the combined
embolization protocol was also required for tumors with
diameters of 2–3 cm to achieve near-stasis. This evidence
could potentially indicate a different vascular maturation of
the feeder according to dimension of the target tumor, thus
requiring different load and dimension of DEE.
This approach involved embolization with PEG micro-
spheres loaded with epirubicin, an anthracycline antibiotic
with a toxicity profile characterized by myelosuppression,
acute and chronic cardiotoxicity, mucositis, and alopecia.
The cumulative dose limit for doxorubicin as a systemic
therapy is 400–550 mg/m2, whereas the dose limit for epi-
rubicin is 900 mg/m2, thus making it a safer choice for
patients with HCC, who generally present with different
comorbidities (cirrhosis and hepatic, cardiac, and renal
dysfunctions) (19,20). It is worth noting that the mean re-
sidual volume of tumors categorized as PR at 1 month after
treatment was 48% of the tumor volume before the pro-
cedure, and further curative percutaneous ablation in 3 pa-
tients was performed.
In patients presenting with 1 or 2 lesions, different
catheter-based modalities may be offered. In particular, ra-
diation segmentectomy (RS), a radioembolization procedure
performed within a single liver segment, has been investi-
gated. Comparing the present clinical results with results of
RS procedures reported in the literature (21) shows the
Figure 4. Score of superselectivity. (a) A score of 0 indicates superselective tumoral feeder catheterization without extratumoral
embolization. (b) A score of 1 indicates embolization of 1 subsegmental nontarget vessel. Digital subtraction angiography used.
Figure 5. Optical microscopy (hematoxylin and eosin stain) of the tumor shown in Figure 2 after liver transplantation. (a) Slide
demonstrates a completely necrotic tumor with 2 different-sized microspheres (magnification 1). (b) Magnification of peritumoral
vessels demonstrate how the identified microspheres are mainly 200 μm ± 50 microspheres (magnification 10). (c) Magnification of
intralesion space demonstrates how the smaller caliber microspheres are mainly located intralesionally (magnification 10).
Table 3. Tumor Analysis
Size Stasis Obtained Only with 100 μm ± 25 Stasis Obtained with Both 100 μm ± 25 and 200 μm ± 50
No. Tumors 100 μm ± 25 Epirubicin
Dose (mg)
No. Tumors 100 μm ± 25 200 μm ± 50 Epirubicin
Dose (mg)
< 2 cm 10 47.5% 23.75 11 100% 12.72% 56.36
2–3 cm 0 0 0 14 100% 30.17% 65.58
 3 cm 0 0 0 19 100% 72.5% 86.25
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2019 7absence of serious (grade 3–4) AEs in the DEE transcatheter
arterial chemoembolization cohort, and despite a higher
reported rate of 12-month objective response with RS (RS
83% vs DEE transcatheter arterial chemoembolization
63.6%) similar 12-month DC were observed (RS 86% vs
DEE transcatheter arterial chemoembolization 90.69%). Afuture cost analysis study is needed to determine if DEE
transcatheter arterial chemoembolization could result in
savings in this patient setting compared with RS.
With regard to AEs, this series demonstrated a lower
incidence than reported in the literature (8,22). In particular,
this series had a PES incidence of 7.69% and an
Table 4. Regression Analysis
Set Outcome P R2 (Cox and Snell) R2 (Nagelkerke) AUC HL test, P (c2)
Lab CR 3–6 months .004 .54 .74 0.95 .96 (2.0)
Lab DC 9–12 months .02 .56 .86 0.98
Hep Status DC 3–6 months .0012 .36 .87 0.99
Tum Char CR baseline .008 .40 .55 0.86 .10 (14.8)
Tum Char CR 3–6 months .014 .48 .66 0.91 .70 (5.7)
AUC ¼ area under the curve; CR ¼ complete response; DC ¼ disease control; Hep Status ¼ hepatic status (Child-Pugh, Model for End-
Stage Liver Disease, Model for End-Stage Liver Disease Sodium, and a-fetoprotein); HL ¼ Hosmer-Lemeshow; Lab ¼ laboratory
analysis (aspartate aminotransferase, alanine aminotransferase, a-fetoprotein, g-glutamyltransferase, total bilirubin, direct bilirubin,
albumin, number of platelets, white blood cells, number of neutrophils, percentage of neutrophils, international normalized ratio,
creatinine, and sodium); Tum Char ¼ tumor characteristics (monofocal, monolobar, lesion number, diameter, volume, hypervascular,
fat degeneration, capsule, infiltration, shadow margin, partial necrosis, and portal thrombosis).
Figure 6. (a) Receiver operating characteristic curve of tumor characteristics (Tum Char) for CR at baseline. (b) Comparison of receiver
operating characteristic curve of laboratory analysis (Lab) and tumor characteristics for CR at 3–6 months. (c, d) Receiver operating
characteristic curves of laboratory analysis for DC at 9–12 months (c) and hepatic status (Hep Status) for DC at 3–6 months (d).
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whereas Malagari et al (8), using doxorubicin preloaded
HepaSphere (Merit Medical Systems, Inc, South Jordan,
Utah) 30–60 μm microspheres, reported a PES incidence of18.5% in their series of embolization involving 1 segment in
69.3% of procedures and 2 segments in 30.7% of proced-
ures. Mason et al (23) reported a PES prevalence of 36%
with a similar study setup. In addition, Monier et al (24)
Volume ▪ ▪ Number ▪ ▪ Month ▪ 2019 9reported an overall bile injury rate of 32.5% in patients with
HCC receiving DEE transcatheter arterial chemo-
embolization. The observed rate of AEs, mainly grade 1 or
2, could be explained by the fact that all procedures were
highly selective (scores of 0 and 1).
Although the proposed embolization protocol was associ-
ated with a statistically significant increase between preop-
erative and postoperative neutrophil percentages, this finding
was not associated with clinically relevant complications. In
the logistic regression analysis, no single parameter analyzed
alone had enough power to predict the oncologic response at
different time points (except for albumin for CR baseline).
This finding is not in line with the results of Vesselle et al
(25), who reported that tumor size is 1 factor that influences
CR at 30–60 days of follow-up. This discrepancy may be due
to a multifactor model comprising weighting parameters in-
side the corresponding data set, which reflects better the
HCC/transcatheter arterial chemoembolization system
complexity. These data are corroborated by Ishikawa et al
(26), who found no correlation between a-fetoprotein and
tumor size with tumor recurrence using Cox analysis. Further
studies, possibly with a control group, are necessary to vali-
date this model and to create a score to predict a priori
transcatheter arterial chemoembolization results.
This study has several limitations. First, the enrolled
sample size (36 patients; 54 treated tumors) is small. Sec-
ond, it was a single-arm experience without control for other
embolization protocols, in particular, with regard to the
microsphere diameter or to the drug used. Third, despite
having strictly standardized the embolization protocol, the
amount of microsphere and drug administered to each lesion
remains unpredictable, so a proportion of patients received
only the 100 μm ± 25 microspheres. A correlation between
the target lesion diameter and the need for using the 200-μm
drug-eluting embolics was required to achieve stasis in all
lesions > 2 cm. The combined microsphere sizing strategy
is technically feasible with acceptable results in terms of
effectiveness and toxicities.
In conclusion, the proposed combined embolization pro-
tocol consisting of sequential administration of 100 μm ± 25
and 200 μm ± 50 PEG microspheres preloaded with epi-
rubicin showed sustained CR and DC rates of 60% and
90%, respectively, up to 15–18 months from the initial
treatment. Randomized controlled studies are needed to
compare the oncologic outcome of different materials, cal-
ibers, and drugs of DEE transcatheter arterial chemo-
embolization protocols.REFERENCES
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